tiprankstipranks
Trending News
More News >
Virbac SA (FR:VIRP)
:VIRP
Advertisement

Virbac SA (VIRP) AI Stock Analysis

Compare
9 Followers

Top Page

FR:VIRP

Virbac SA

(VIRP)

Select Model
Select Model
Select Model
Outperform 73 (OpenAI - 4o)
Rating:73Outperform
Price Target:
€372.00
▲(2.76% Upside)
Virbac SA's strong financial performance is the most significant factor, supported by stable revenue and profit growth, low leverage, and solid cash flow. Technical analysis and valuation provide a balanced view, with no significant bullish or bearish signals.
Positive Factors
Negative Factors

Virbac SA (VIRP) vs. iShares MSCI France ETF (EWQ)

Virbac SA Business Overview & Revenue Model

Company DescriptionVirbac SA is a global animal health company headquartered in France, specializing in the development, production, and marketing of a wide range of veterinary products. Established in 1964, Virbac focuses primarily on companion animals, such as dogs and cats, as well as livestock, offering pharmaceuticals, vaccines, and diagnostic products. The company operates in various sectors including parasitology, dermatology, and nutrition, aiming to improve the health and well-being of animals worldwide.
How the Company Makes MoneyVirbac generates revenue primarily through the sale of its veterinary products, which include pharmaceuticals, vaccines, and nutritional supplements for both companion animals and livestock. The company operates a diversified revenue model, with key revenue streams coming from prescription products, over-the-counter medicines, and specialized dietary products. Virbac's strategic partnerships with veterinary clinics, animal health distributors, and research institutions enhance its market reach and product development capabilities. Additionally, the company invests in research and development to innovate new treatments and expand its product portfolio, which contributes significantly to its earnings. Geographic expansion into emerging markets also plays a critical role in driving revenue growth.

Virbac SA Financial Statement Overview

Summary
Virbac SA demonstrates strong financial performance with consistent revenue growth, robust profitability margins, and effective cost management. The balance sheet is stable with minimal leverage, and cash flow generation is solid, though there is room for improvement in free cash flow conversion.
Income Statement
85
Very Positive
Virbac SA demonstrates a strong income statement with consistent revenue growth over the years. Gross Profit Margin in 2024 is approximately 67.4%, reflecting efficient cost management. Net Profit Margin stands at about 10.4%, indicating a solid profitability level. EBIT Margin of 15.5% and EBITDA Margin of 20.4% showcase robust operational efficiency. Revenue grew by approximately 12.1% from 2023 to 2024, indicating a healthy upward trajectory. Overall, the company shows strong profitability and growth, with a continuous positive trend.
Balance Sheet
80
Positive
The balance sheet of Virbac SA is stable with a low Debt-to-Equity Ratio of 0.04, indicating minimal leverage and financial risk. Return on Equity (ROE) is approximately 13.9%, showcasing effective utilization of shareholder equity to generate profits. The Equity Ratio of 56.4% suggests a solid capital structure with a significant portion of assets financed by equity. These metrics indicate financial stability and a well-managed balance sheet with minimal debt risk.
Cash Flow
78
Positive
Virbac SA's cash flow statement shows solid cash generation capabilities with a Free Cash Flow Growth Rate of approximately 128.5% from 2023 to 2024. The Operating Cash Flow to Net Income Ratio is about 1.4, indicating good cash conversion. Free Cash Flow to Net Income Ratio stands at 0.93, reflecting efficient management of capital expenses. The company exhibits strong cash flow management, though a higher free cash flow conversion ratio would further enhance its cash flow position.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.43B1.40B1.25B1.22B1.06B934.20M
Gross Profit952.21M937.60M809.60M427.27M378.38M290.41M
EBITDA252.83M276.26M230.65M215.55M199.46M231.67M
Net Income133.03M145.29M121.30M121.97M113.16M136.04M
Balance Sheet
Total Assets1.82B1.85B1.46B1.36B1.22B1.11B
Cash, Cash Equivalents and Short-Term Investments128.67M149.63M175.91M177.38M172.79M181.89M
Total Debt325.62M307.01M120.11M96.86M95.37M116.22M
Total Liabilities750.28M805.12M545.81M521.17M498.84M454.28M
Stockholders Equity1.07B1.04B900.30M839.33M724.93M620.97M
Cash Flow
Free Cash Flow96.89M134.97M77.60M45.41M79.13M81.23M
Operating Cash Flow193.48M204.22M118.64M98.98M126.29M110.22M
Investing Cash Flow-133.80M-428.69M-121.87M-54.83M-51.21M339.52M
Financing Cash Flow-77.75M138.59M-2.56M-34.76M-91.69M-349.89M

Virbac SA Technical Analysis

Technical Analysis Sentiment
Positive
Last Price362.00
Price Trends
50DMA
326.50
Positive
100DMA
330.67
Positive
200DMA
319.16
Positive
Market Momentum
MACD
10.23
Negative
RSI
74.72
Negative
STOCH
98.15
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:VIRP, the sentiment is Positive. The current price of 362 is above the 20-day moving average (MA) of 328.35, above the 50-day MA of 326.50, and above the 200-day MA of 319.16, indicating a bullish trend. The MACD of 10.23 indicates Negative momentum. The RSI at 74.72 is Negative, neither overbought nor oversold. The STOCH value of 98.15 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:VIRP.

Virbac SA Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
$108.25B12.028.39%4.45%-9.82%119.10%
€3.04B22.8512.92%0.40%6.97%-5.59%
€924.81M15.3710.80%1.14%-0.95%27.67%
€9.41B21.1110.82%1.17%9.57%-34.30%
€490.52M25.105.22%4.32%4.80%-18.25%
€1.19B-57.86181.43%28.76%
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FR:VIRP
Virbac SA
362.00
14.07
4.04%
FR:BOI
Boiron SA
27.75
-2.90
-9.46%
FR:IPN
Ipsen
119.50
7.81
6.99%
FR:VETO
VETOQUINOL
78.80
-0.45
-0.57%
FR:SAN
Sanofi
88.13
-7.69
-8.02%
FR:MEDCL
MedinCell SA
36.32
21.28
141.49%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 18, 2025